Answers are grounded in this paper and cite their sources.
Myasthenia gravis is a common autoimmune disease in which patients experience weakness primarily in the ocular, respiratory, bulbar, and limb muscles. Although the symptoms of most patients with myasthenia gravis are well controlled with conventional immunotherapies, about 15% of them experience a refractory disease. This systematic review will focus on the safety and efficacy of monoclonal antibodies, specifically rituximab and eculizumab, in treating myasthenia gravis
No takes yet. Share an insight, caveat, or question.
Suryadevara et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: